X
Xiaoling Xu
Researcher at University of Science and Technology of China
Publications - 12
Citations - 3784
Xiaoling Xu is an academic researcher from University of Science and Technology of China. The author has contributed to research in topics: Tocilizumab & Clinical trial. The author has an hindex of 6, co-authored 9 publications receiving 2950 citations.
Papers
More filters
Journal ArticleDOI
Effective treatment of severe COVID-19 patients with tocilizumab.
Xiaoling Xu,Mingfeng Han,Tiantian Li,Wei Sun,Dongsheng Wang,Binqing Fu,Yonggang Zhou,Xiaohu Zheng,Yun Yang,Xiuyong Li,Xiaohua Zhang,Aijun Pan,Haiming Wei +12 more
TL;DR: Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.
Journal ArticleDOI
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Yonggang Zhou,Binqing Fu,Xiaohu Zheng,Dongsheng Wang,Changcheng Zhao,Yingjie Qi,Rui Sun,Zhigang Tian,Xiaoling Xu,Haiming Wei +9 more
TL;DR: The results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology and suggest that monoclonal antibodies targeting GM-CSF or interleukin 6 may be effective in blocking inflammatory storms and, therefore, be a promising treatment of severe COVID-19 patients.
Journal ArticleDOI
Why tocilizumab could be an effective treatment for severe COVID-19?
TL;DR: It is suggested that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.
Posted ContentDOI
Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus
Yonggang Zhou,Binqing Fu,Xiaohu Zheng,Dongsheng Wang,Changcheng Zhao,Yingjie Qi,Rui Sun,Zhigang Tian,Xiaoling Xu,Haiming Wei +9 more
TL;DR: The results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology and suggest that monoclonal antibody that targets the GM-CSF or interleukin 6 receptor may potentially curb immunopathology caused by 2019-nCoV and consequently win more time for virus clearance.
Journal ArticleDOI
Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.
Dongsheng Wang,Binqing Fu,Zhen Peng,Dongliang Yang,Mingfeng Han,Min Li,Yun Yang,Tianjun Yang,Liangye Sun,Wei Li,Wei Shi,Xin Yao,Yan Ma,Fei Xu,Xiao jing Wang,Jun Chen,Daqing Xia,Yubei Sun,Lin Dong,Jumei Wang,Xiaoyu Zhu,Min Zhang,Yonggang Zhou,Aijun Pan,Xiaowen Hu,Xiaodong Mei,Haiming Wei,Xiaoling Xu +27 more
TL;DR: Tocilizumab has been reported to attenuate the "cytokine storm" in COVID-19 patients as mentioned in this paper, but the difference was not statistically significant (94.12% vs 87.10%, rate difference 95% CI-7.19%-21.23%, P = 0.4133).